Labelling of CTMP with technetium-99m as radiopharmaceutical for bone cancer seeking

Radiopharmaceutical for bone cancer seeking was developed in variable compound labelled with technetium-99m, formally pyrophosphate compound and diphosphonate compound such as methylenediphosphonate (^99mTc-MDP), hydroxyethylene diphosphonate (^99mTc-HEDP) and hydroxy methylene diphosphonate (^99mTc-HMDP). Either pyrophosphate or diphosphonate still unsatisfied to use as radiopharmaceutical for bone cancer seeking because the high accumulation in lever, muscle and blood. The compound of tetraaminotetraphosphonate groups have the higher affinity in bone because of four phosphonate and four amine groups. This experiment was done to label the compound group especially 1,4,8, 1-tetraazacyclotetradecyl-1,4,8,11-tetramethylene phosphonic acid (CTMP) with technetium-99m radionuclide. To obtain the maximal labelling result, some parameters such as pH, amount of SnCl₂ reductor and ligan, time and temperature of reaction are optimized. The optimal condition obtained were pH of 4-6, 100 µg of SnCl₂ reductor, 500 µg of CTMP ligand and labelling time of 10 minutes in boiling water or 30 minutes in room temperature, with labelling efficiency was >95 %. (author)